Medline ® Abstract for Reference 27
of 'Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography'
27
TI
Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
AU
de Lédinghen V, Vergniol J, Gonzalez C, Foucher J, Maury E, Chemineau L, Villars S, Gin H, Rigalleau V
SO
Dig Liver Dis. 2012 May;44(5):413-8. Epub 2012 Jan 27.
BACKGROUND:
Patients with diabetes are at risk for nonalcoholic fatty liver disease leading to cirrhosis. Existing guidelines do not advocate screening for liver related complications amongst persons with diabetes.
AIM:
The aim of this prospective study was to identify patients with severe liver fibrosis amongst patients hospitalized for their diabetes, using non-invasive methods, and to evaluate factors associated with severe fibrosis.
METHODS:
Consecutive patients with type 1 or 2 diabetes had clinical, biological parameters and liver fibrosis evaluation. Severe fibrosis was predicted when FibroTest was>0.59 or liver stiffness>8.7 kPa.
RESULTS:
A total of 277 patients were evaluated (type 1 diabetes 52%). The prevalence of severe fibrosis was 15.5%. By univariate analysis, factors associated with severe fibrosis were age, type 2 diabetes, body mass index, metabolic syndrome, previous cardiovascular events, no retinopathy, past history of foot ulcer, and elevated alanine aminotransferase. By multivariate analysis, factors associated with severe fibrosis were age>50 years, type 2 diabetes, no retinopathy, and past history of foot ulcer.
CONCLUSION:
This study showed an elevated prevalence of severe fibrosis in hospitalized diabetic patients, especially patients aged 50 years or older with type 2 diabetes, or with a past history of foot ulcer.
AD
Service d'Hépato-Gastroentérologie, Hôpital Haut-Lévêque, Pessac, France. victor.deledinghen@chu-bordeaux.fr
PMID
